Acquired reactive perforating collagenosis secondary to Cabozantinib: A case report and literature review

Abstract

Acquired perforating dermatoses (APD) encompass a group of skin conditions distinguished by transepidermal elimination of dermal components. Acquired reactive perforating collagenosis (ARPC), a subtype of APD, has been reported most commonly in association with diabetes mellitus, chronic renal failure, and medications. In this report, we identify a novel case of ARPC secondary to Cabozantinib treatment.